A recent review published in The Lancet Diabetes and Endocrinology analyzed the effects of common treatments for insomnia and obstructive sleep apnoea on sleep and glucose regulation, reports Medical News Bulletin.
Compared to the general population, sleep problems such as insomnia and obstructive sleep apnoea (OSA) are more common in people with type 2 diabetes. There is evidence supporting an association between insomnia and OSA and cardiometabolic changes (such as high blood pressure and systemic insulin resistance) that have a negative impact on the pathophysiology of type 2 diabetes.
Therefore, improving sleep problems in patients with type 2 diabetes could subsequently help treat diabetes, as sufficient and quality sleep is important for maintaining optimal cardiometabolic health. Previous studies have shown that a substantial number of patients with type 2 diabetes suffer from regular symptoms of insomnia.